Enlivex Therapeutics Ltd
ENLV
View Detailed Chart
0.835USD
+0.003+0.40%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
20.28MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.40%
5 Days
-10.12%
1 Month
-8.50%
6 Months
-23.40%
Year to Date
-28.64%
1 Year
-32.67%
View Detailed Chart
TradingKey Stock Score of Enlivex Therapeutics Ltd
Currency: USD Updated: 2025-12-19Key Insights
Enlivex Therapeutics Ltd's fundamentals are relatively weak, and its growth potential is high.Its valuation is considered fairly valued, ranking 193/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7.00.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enlivex Therapeutics Ltd's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
7.000
Target Price
+536.36%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Enlivex Therapeutics Ltd Highlights
StrengthsRisks
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Fairly Valued
The company’s latest PE is -1.51, at a medium 3-year percentile range.
Held by James Simons
Star Investor James Simons holds 157.29K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 5.81.
Enlivex Therapeutics Ltd News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Enlivex Therapeutics Ltd Info
Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.
Ticker SymbolENLV
CompanyEnlivex Therapeutics Ltd
CEOHershkovitz (Oren)
Websitehttps://www.enlivex.com/
FAQs
What is the current price of Enlivex Therapeutics Ltd (ENLV)?
The current price of Enlivex Therapeutics Ltd (ENLV) is 0.835.
What is the symbol of Enlivex Therapeutics Ltd?
The ticker symbol of Enlivex Therapeutics Ltd is ENLV.
What is the 52-week high of Enlivex Therapeutics Ltd?
The 52-week high of Enlivex Therapeutics Ltd is 2.100.
What is the 52-week low of Enlivex Therapeutics Ltd?
The 52-week low of Enlivex Therapeutics Ltd is 0.794.
What is the market capitalization of Enlivex Therapeutics Ltd?
The market capitalization of Enlivex Therapeutics Ltd is 20.28M.
What is the net income of Enlivex Therapeutics Ltd?
The net income of Enlivex Therapeutics Ltd is -15.01M.
Is Enlivex Therapeutics Ltd (ENLV) currently rated as Buy, Hold, or Sell?
According to analysts, Enlivex Therapeutics Ltd (ENLV) has an overall rating of Buy, with a price target of 7.000.
What is the Earnings Per Share (EPS TTM) of Enlivex Therapeutics Ltd (ENLV)?
The Earnings Per Share (EPS TTM) of Enlivex Therapeutics Ltd (ENLV) is -0.551.
Related Instruments
+1.32%
-0.88%
+1.75%
+0.83%
+0.60%
+0.38%
+0.91%
+1.03%
+2.32%
+0.60%
+0.40%
+1.97%
+1.63%
+1.21%
+0.65%
+0.66%
+2.57%
0.00%
-0.44%
+1.06%
